270 related articles for article (PubMed ID: 31926582)
21. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
[TBL] [Abstract][Full Text] [Related]
22. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
23. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab.
Cafuir L; Lawson D; Desai N; Kesner V; Voloschin A
J Immunother Cancer; 2018 Jan; 6(1):11. PubMed ID: 29382383
[TBL] [Abstract][Full Text] [Related]
27. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
28. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
Gambichler T; Stockfleth E; Susok L
J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
[TBL] [Abstract][Full Text] [Related]
29. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
[TBL] [Abstract][Full Text] [Related]
30. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
31. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
32. Silent acute appendicitis revealed by PET-CT during treatment with ipilimumab and nivolumab: a new immune-related adverse event.
Mangas C; Leoni-Parvex S; Spataro V
Cancer Immunol Immunother; 2020 Nov; 69(11):2409-2410. PubMed ID: 32964272
[No Abstract] [Full Text] [Related]
33. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
[No Abstract] [Full Text] [Related]
34. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
[TBL] [Abstract][Full Text] [Related]
35. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
36. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy.
Lucke IM; Wieske L; van der Kooi AJ; van Schaik IN; Eftimov F; Verhamme C
J Peripher Nerv Syst; 2019 Jun; 24(2):174-179. PubMed ID: 31090121
[TBL] [Abstract][Full Text] [Related]
38. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
[No Abstract] [Full Text] [Related]
39. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
Latchman J; Guastella A; Tofthagen C
Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
[TBL] [Abstract][Full Text] [Related]
40. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
